The MetMemory Trial: Preventing cognitive decline with metformin. A randomised controlled trial.
An Australian-led research project at the Garvan Institute, funded by the National Health and Medical Research Council, is recruiting volunteers for a 3-year study examining the effects of metformin on cognition, brain anatomy and early signs of dementia.
Metformin is a safe medication used to treat diabetes, but also other metabolic/ hormonal conditions.
Our aims are to slow loss of memory and other aspects of cognition with ageing, and examine whether metformin affects other aspects of metabolism, inflammation and the ageing process.
The study has been approved by the St Vincent's Hospital HREC team (ETH01652).
Participation
Do you live in the greater Sydney region and are you interested in participating in a placebo-controlled study aiming to slow cognitive decline, using a safe medication used to treat diabetes and metabolic conditions? We are seeking participants who meet the following inclusion criteria:
- age 60+ years
- overweight or obese (or waist measurement women>80 cm, men>94cm
- live within the greater Sydney region
- no diabetes
- no severe heart failure
- no severe kidney disease
- not currently taking metformin
- has concerns about their memory
Participants must be willing and able to commit to 3-monthly visits at the Garvan Institute for the 3-year duration of the study.
For more information, contact by telephone or email:
Participant duration
3 years
Available to people living in
NSW
Study begins
Saturday, 1 October 2022
Contact
To find out more about this study, contact:
Elza Plotz
Garvan Institute of Medical Research
NSW
